HT1197-luc Orthotopic Mouse Model Service for Bladder Cancer

The HT1197-luc orthotopic mouse model harnesses one of the most extensively molecularly profiled human bladder cancer cell lines, enabling bioluminescence-tracked evaluation of intravesical agents, targeted therapies, and combination regimens within an immunodeficient orthotopic setting. Alfa Cytology generates this model with validated luciferase expression, optimized intravesical delivery protocols, and integrated longitudinal imaging—providing sponsors with quantitative tumor kinetics and histopathological depth to advance preclinical compound assessment.

Overview of HT1197-luc Orthotopic Mouse Model for Bladder Cancer

The HT-1197 cell line was established in 1977 from a transitional cell carcinoma of the urinary bladder and has since become one of the most comprehensively characterized human bladder cancer lines, profiled across all five major molecular panels—CCLE, UBC-40, GDSC, TCPA, and BLA-40. Genetically, HT-1197 harbors activating mutations in NRAS and PIK3CA, driving constitutive MAPK and PI3K/AKT pathway signaling. The line carries a distinctive C-terminal TP53 point mutation at codon 365 (His→Arg) within the tetramerization domain—a rare alteration that disrupts oligomerization without ablating DNA-binding capacity—alongside MDM2 overexpression that dampens wild-type p53 activity. Molecularly classified as basal-squamous, HT-1197 expresses high levels of basal cytokeratins and exhibits a grade IV, stage ≥T2 phenotype with robust tumorigenicity in both mice and hamsters.

Fig 1. Immunofluorescence (green), western blot, and scratch assay (0H/24H) of HT1197 and HT1376 TM (Wu, Chun-Te, et al., 2014)

When engineered with a stable firefly luciferase reporter and instilled intravesically into immunodeficient hosts, HT1197-luc cells engraft within the bladder wall and generate bioluminescence signals that scale linearly with viable tumor burden. The model supports evaluation of intravesical chemotherapy, targeted agents against RAS/PI3K nodes, and DNA damage response modulators—with the luciferase tag enabling non-invasive, repeated quantification that reduces inter-animal variability and refines humane endpoints. Given HT-1197’s relatively slow doubling time (~61 hours), tumors establish over a slightly extended window compared to more rapidly proliferating lines, offering a measured timeline for therapeutic intervention and pharmacodynamic assessment.

Cell Line Information: HT1197-luc

HT1197-luc is a firefly luciferase-expressing derivative of the HT-1197 human bladder transitional cell carcinoma line, one of the most extensively molecularly characterized bladder cancer cell lines available. The parental line has been profiled across CCLE, UBC-40, GDSC, TCPA, and BLA-40 panels, providing an unparalleled depth of genomic, transcriptomic, and proteomic annotation for preclinical modeling.

Our Services

Alfa Cytology delivers the HT1197-luc orthotopic bladder cancer model as a fully integrated preclinical service, capitalizing on the line’s deep molecular annotation to inform study design and endpoint selection. Our surgical team performs intravesical instillation with poly-L-lysine preconditioning and urethral clamping under continuous anesthesia, achieving reproducible engraftment while preserving the basal-squamous tumor phenotype. Weekly bioluminescence imaging sessions are calibrated to HT-1197’s slower growth kinetics, and terminal analyses include H&E histopathology, proliferation and apoptosis IHC, and RAS/PI3K pathway biomarker profiling—providing a mechanistically grounded dataset for your therapeutic program.

Workflow of HT1197-luc Orthotopic Mouse Model Construction

Construction of the HT1197-luc orthotopic bladder tumor model follows a standardized intravesical instillation protocol optimized for this slower-growing, basal-squamous human line. The procedure centers on transurethral delivery into immunodeficient hosts, with bladder preconditioning and controlled dwell times calibrated to maximize engraftment despite HT-1197’s relatively extended doubling time. Luciferase validation is performed at multiple checkpoints to ensure quantitative signal fidelity throughout the study.

1. Luciferase Cell Line Validation and Banking: HT1197-luc cells are verified for stable luciferase expression via in vitro bioluminescence assays, confirming linear photon output across the anticipated tumor burden range. Mycoplasma PCR, STR authentication, and viability testing (>85% by trypan blue exclusion) are performed on each master cell bank aliquot prior to release.
2. Host Preparation and Anesthesia: Female athymic nude mice, 6–8 weeks of age, are acclimatized for at least one week. On the day of surgery, mice are anesthetized with isoflurane (3% induction, 1.8% maintenance at 2 L/min oxygen), placed on a heated pad, and monitored for respiratory pattern and skin color. Ophthalmic ointment is applied to prevent corneal desiccation.
3. Bladder Evacuation and Preconditioning: The bladder is gently emptied by manual compression of the lower abdomen. A lubricated 24-gauge catheter is advanced transurethrally to approximately 1 cm depth. Fifty microliters of 0.1% poly-L-lysine (prewarmed to 37 °C) is instilled and allowed to dwell for 15 minutes to disrupt the urothelial glycosaminoglycan barrier and enhance HT1197-luc cell adhesion.
4. Tumor Cell Instillation and Urethral Clamping: HT1197-luc cells are resuspended in complete growth medium to maintain viability during the procedure. A suspension of 3×10⁶ cells in 50 µL is slowly instilled through the catheter. A lightweight surgical clamp is applied around the urethral meatus to prevent leakage, and the cell suspension is retained in the bladder for 1.5 hours under continuous anesthesia. This extended dwell time accommodates HT-1197’s slower adhesion kinetics and promotes robust tumor cell attachment.
5. Post-Procedure Recovery: Following the dwell period, the clamp and catheter are removed, and the bladder is allowed to empty spontaneously. Mice are transferred to a heated recovery chamber and monitored until fully ambulatory and urinating normally. Analgesia is administered according to institutional IACUC guidelines. Body weights are recorded daily for the first three post-operative days and twice weekly thereafter.
6. Longitudinal Bioluminescence Imaging and Endpoint Assessment: Tumor engraftment and growth are monitored via bioluminescence imaging (IVIS or equivalent) performed every 3–7 days following intraperitoneal luciferin injection. Given HT-1197’s ~61-hour doubling time, imaging intervals are spaced to capture meaningful kinetic changes without excessive animal handling. Photon flux is quantified within standardized regions of interest and correlated with terminal bladder weight. At study endpoint, bladders are harvested for H&E staining, IHC profiling of Ki-67, cleaved caspase-3, and RAS/PI3K pathway markers, and bioluminescence-histopathology correlation validation.

Fig 2. HT1197-luc Orthotopic Mouse Model construction workflow.

Case Study-HT1197-luc Orthotopic Mouse Model Development

In a preclinical engagement, Alfa Cytology established the HT1197-luc orthotopic model to evaluate the intravesical efficacy of a novel therapeutic candidate in a basal-squamous bladder cancer context. Following poly-L-lysine preconditioning and intravesical instillation, tumors were allowed to engraft for two weeks, after which bioluminescence imaging confirmed tumor take and provided baseline quantification across the cohort. Animals were randomized into vehicle control and treatment groups, with bioluminescence readouts captured at regular intervals to track tumor kinetics throughout the dosing period. At study termination, excised bladders underwent gravimetric analysis and comprehensive histopathological evaluation, including H&E staining and IHC profiling of proliferation markers and RAS/PI3K pathway components. The resulting dataset provided quantitative evidence of tumor growth modulation, supported by correlative biomarker changes, and informed the sponsor’s preclinical development strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HT1197-luc orthotopic bladder cancer study means leveraging a deeply annotated model platform managed by scientists who understand the nuances of basal-squamous biology, slower growth kinetics, and quantitative bioluminescence imaging.

• Deep Molecular Annotation: HT-1197 is one of only three bladder cancer lines profiled across all five major molecular panels, providing an unmatched foundation for rational study design and biomarker selection.
• Bioluminescence-Integrated Kinetics: Stable luciferase expression enables precise, non-invasive tumor burden quantification at multiple timepoints, reducing cohort size and refining statistical power.
• RAS/PI3K Pathway Expertise: Our team has specialized experience with NRAS- and PIK3CA-driven models, enabling targeted pharmacodynamic readouts and mechanism-of-action studies.
• Calibrated Imaging Schedules: Imaging intervals are tailored to HT-1197’s ~61-hour doubling time, ensuring meaningful kinetic data without unnecessary animal handling.
• Comprehensive Endpoint Portfolio: Terminal assessments include bladder weight, H&E histopathology, proliferation and apoptosis IHC, and RAS/PI3K pathway biomarker profiling.
• Regulatory-Ready Documentation: All studies are conducted under IACUC-approved protocols with full traceability, supporting IND-enabling and publication-grade data packages.

Contact Us

Ready to advance your bladder cancer therapeutic program with the deeply characterized HT1197-luc orthotopic model? Reach out to us today to discuss your study requirements, receive a customized proposal, and explore how Alfa Cytology's preclinical expertise can accelerate your compound’s path from target validation to IND-enabling data.

For research use only. Not intended for any clinical use.